Arthneeti
Financial resultsMajor developmentFiled on BSE ·

Dr. Agarwal's Health Care approves H1 FY27 results; Amar Agarwal Executive Chairman

Dr Agarwals Health Care · Healthcare Services

Arthneeti Research DeskPublished 1 min read
₹29.7 CrFinancial results

Key highlights

  • Approved unaudited standalone and consolidated results for Q2 and H1 FY27 ended September 30, 2026; standalone financing cash flow used ₹29.71 crore in H1 FY27.
  • Scheme of Amalgamation effective November 1, 2026, merging Dr. Agarwal's Eye Hospital Limited into Dr. Agarwal's Health Care Limited; 1,51,90,373 equity shares pending issuance.
  • Dr. Amar Agarwal appointed and re-designated Executive Chairman (Whole-Time Director) for three years from November 1, 2026, subject to shareholder approval.

Why it's rated major development: the year-on-year change is 56% (50% or more)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Consolidated And Standalone Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Waaree Energies Ltd

Electrical Equipment

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Dr Agarwals Health Care

Other financial results filings this fortnight

All financial results filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.